Who is at Risk for ATTRv V30M Amyloidosis?
At a Glance
The primary risk factor for ATTRv V30M (V50M) amyloidosis is inheriting the mutated TTR gene from a parent, which carries a 50% chance. While it occurs globally, risk is highest in endemic regions like Portugal, Sweden, and Japan, with symptoms and onset age varying by genetic background.
In this answer
4 sections
Hereditary transthyretin-mediated amyloidosis (ATTRv) with the V30M mutation is a genetic condition [1]. To understand your risk, it helps to know how the disease works: the mutation causes a protein called transthyretin to misfold and clump together into deposits (amyloid) that damage nerves and organs [1].
(Note: While historically called V30M, modern genetic tests often include an extra protein segment in their sequencing, so your lab report may label your mutation as V50M or p.Val50Met. These refer to the exact same condition.)
The primary risk factor is inheriting the mutated TTR gene from a parent [1][2]. Because it is an autosomal dominant condition, a person only needs to inherit the gene from one parent to be at risk—meaning there is a 50% chance of passing the mutation to each child [1]. While cases occur globally, the mutation is most commonly found in specific geographic clusters known as endemic regions, primarily Portugal, Sweden, and Japan [3][4].
Endemic Regions and Genetic Origins
The term “endemic” refers to areas where a disease is unusually common. For ATTRv V30M (or V50M), large clusters of affected families have historically lived in specific areas of Portugal, Sweden, and Japan [3][5]. In countries like Brazil, the mutation is also very common, primarily due to historical migration from Portugal [6].
While the mutation in the major endemic countries often shares a common genetic background [3], genetic testing reveals that the mutation has multiple, independent ancestral origins [7]. This means the genetic change occurred spontaneously in different people around the world at different times in history. Consequently, patients without a family history (sporadic cases) or ties to endemic regions can still develop ATTRv V30M [8]. Without a known family history, these individuals often experience significant delays in their diagnosis [9][8].
Early-Onset vs. Late-Onset Disease
The age at which symptoms begin and the specific symptoms a person experiences are strongly influenced by their geographic and genetic background [5][4]. While these are typical presentations, there can be significant overlap, and symptoms can vary even among individuals within the same family [10].
- Early-onset disease: This is most common in Portuguese families (and among those of Portuguese descent, such as in Brazil) [5][6]. Symptoms often begin before the age of 50, sometimes in a person’s 20s or 30s [5][11]. Early-onset typically presents with severe sensory issues (like numbness and tingling from small nerve fiber damage) and early autonomic dysfunction (problems with involuntary body functions like digestion, sweating, and blood pressure) [11][12].
- Late-onset disease: This is more typical in Sweden, Japan, and most non-endemic regions around the world [5][13][14]. Symptoms usually begin after age 50, often in a person’s 60s or older [13][15]. Late-onset cases are more likely to involve damage to larger nerve fibers (causing weakness and loss of deep sensation) and more frequent, severe heart involvement (cardiomyopathy) [16][12].
Penetrance and Additional Risk Factors
Having the V30M mutation does not guarantee a person will develop symptoms; this concept is known as penetrance. Penetrance varies wildly depending on where a family originates:
- High penetrance: In Portuguese families, the likelihood of developing the disease is very high at a younger age [5][17].
- Low penetrance: In Swedish families, penetrance is exceptionally low in early life—estimated at less than 10% by age 40—but rises to around 71% by age 90 [18].
Researchers have identified several other factors that influence risk. Gender plays a role, with males consistently showing a higher risk and earlier onset of the disease [18][19]. There is also a notable parent-of-origin effect: inheriting the mutation from one’s mother is associated with earlier disease onset and a higher likelihood of developing symptoms compared to inheriting it from the father [5][20]. In some families, the disease may develop at a younger age in subsequent generations, a phenomenon genetic counselors sometimes refer to as genetic anticipation [21].
Additionally, other “genetic modifiers” and potentially environmental factors may influence when and how the disease develops [21][22]. Currently, genetic modifiers are areas of ongoing scientific research to explain why the disease varies so much, rather than a standard test your doctor can run to predict your exact risk [21].
What This Means For Your Family
If you or a family member has been diagnosed with ATTRv V30M (V50M) amyloidosis, it is highly recommended to seek genetic counseling. A genetic counselor can help your family navigate the 50% inheritance risk for children and discuss the appropriate age for relatives to consider genetic testing. Identifying the mutation early in family members is increasingly important because modern disease-modifying treatments are now available and are most effective when started early in the disease process.
Common questions in this guide
Is the V30M mutation the same as V50M?
What are the chances of inheriting ATTRv V30M if my parent has it?
What are the most common endemic regions for ATTRv V30M?
What is the difference between early-onset and late-onset ATTRv V30M?
Does inheriting the V30M mutation guarantee I will develop symptoms?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my genetic test results, is my mutation listed as V30M or V50M, and how does this naming convention affect how my medical records are shared between specialists?
- 2.Based on my family's geographic background and medical history, should my monitoring focus more heavily on early-onset nerve issues or late-onset cardiomyopathy?
- 3.At what age do you recommend my children or siblings speak to a genetic counselor about predictive testing for the V30M/V50M mutation?
- 4.Since I have the V30M mutation, what baseline autonomic or cardiac tests should we perform now to ensure we catch any early signs of disease?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (22)
- 1
Hereditary transthyretin-related amyloidosis.
Finsterer J, Iglseder S, Wanschitz J, et al.
Acta neurologica Scandinavica 2019; (139(2)):92-105 doi:10.1111/ane.13035.
PMID: 30295933 - 2
Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.
Chiaro G, Stancanelli C, Koay S, et al.
Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2024; (34(3)):341-352 doi:10.1007/s10286-024-01038-z.
PMID: 38769233 - 3
Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.
Ando Y, Waddington-Cruz M, Sekijima Y, et al.
Orphanet journal of rare diseases 2023; (18(1)):323 doi:10.1186/s13023-023-02910-3.
PMID: 37828588 - 4
Familial Amyloid Polyneuropathy.
Çakar A, Durmuş-Tekçe H, Parman Y
Noro psikiyatri arsivi 2019; (56(2)):150-156 doi:10.29399/npa.23502.
PMID: 31223250 - 5
A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis.
Planté-Bordeneuve V, Gorram F, Olsson M, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2023; (30(3)):313-320 doi:10.1080/13506129.2023.2178891.
PMID: 36994840 - 6
Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS).
Cruz MW, Pinto MV, Pinto LF, et al.
Arquivos de neuro-psiquiatria 2019; (77(2)):96-100 doi:10.1590/0004-282X20180156.
PMID: 30810593 - 7
Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria.
Pavlova Z, Sarafov S, Todorov T, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(4)):219-225 doi:10.1080/13506129.2021.1935230.
PMID: 34076545 - 8
Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V, Grittner U, Beetz C, et al.
Annals of medicine 2021; (53(1)):1787-1796 doi:10.1080/07853890.2021.1988696.
PMID: 34658264 - 9
Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis.
Antunes B, Conceição I, Falcão de Campos C, de Carvalho M
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(2)):929-934 doi:10.1007/s10072-024-07793-1.
PMID: 39387955 - 10
Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis.
Plantone D, Primiano G, Righi D, et al.
Cells 2023; (12(19)) doi:10.3390/cells12192383.
PMID: 37830598 - 11
Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E, Kyriakides T
Current neuropharmacology 2023; (21(3)):471-481 doi:10.2174/1570159X21666221108094736.
PMID: 36366846 - 12
Transthyretin familial amyloid polyneuropathy (TTR-FAP) in Mallorca: a comparison between late- and early-onset disease.
Buades-Reinés J, Raya-Cruz M, Gallego-Lezaún C, et al.
Journal of the peripheral nervous system : JPNS 2016; (21(4)):352-356 doi:10.1111/jns.12180.
PMID: 27403623 - 13
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA, Scheinberg M, Waddington-Cruz M, et al.
Expert review of clinical pharmacology 2019; (12(8)):701-711 doi:10.1080/17512433.2019.1635008.
PMID: 31268366 - 14
Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan.
Konishi H, Abe H, Matsumoto N, et al.
Current therapeutic research, clinical and experimental 2025; (102()):100793 doi:10.1016/j.curtheres.2025.100793.
PMID: 40495907 - 15
Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain.
Silva-Hernández L, Horga Hernández A, Valls Carbó A, et al.
Neurologia 2023; (38(2)):87-92 doi:10.1016/j.nrleng.2020.06.015.
PMID: 36396096 - 16
Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
Pinto MV, Pinto LF, Dias M, et al.
Journal of the neurological sciences 2019; (403()):1-6 doi:10.1016/j.jns.2019.05.030.
PMID: 31163298 - 17
Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center.
Nomura T, Misumi Y, Tasaki M, et al.
Orphanet journal of rare diseases 2025; (20(1)):474 doi:10.1186/s13023-025-04006-6.
PMID: 40898332 - 18
New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden.
Gorram F, Olsson M, Alarcon F, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(2)):84-90 doi:10.1080/13506129.2020.1841623.
PMID: 33146042 - 19
Neuropathy Progression in Acquired Amyloidosis After Domino Liver Transplantation.
Falcão de Campos C, Miranda M, Castro I, et al.
Journal of the peripheral nervous system : JPNS 2025; (30(2)):e70016 doi:10.1111/jns.70016.
PMID: 40194884 - 20
Study of the parent-of-origin effect in monogenic diseases with variable age of onset. Application on ATTRv.
Alarcon F, Planté-Bordeneuve V, Nuel G
PloS one 2023; (18(8)):e0288958 doi:10.1371/journal.pone.0288958.
PMID: 37561731 - 21
Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis.
Alves-Ferreira M, Azevedo A, Coelho T, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(2)):100-106 doi:10.1080/13506129.2020.1857236.
PMID: 33461327 - 22
Hereditary Transthyretin Amyloidosis (hATTR) with Polyneuropathy Clusters Are Located in Ancient Mining Districts: A Possible Geochemical Origin of the Disease.
Roos PM, Wärmländer SKTS
Biomolecules 2024; (14(6)) doi:10.3390/biom14060652.
PMID: 38927056
This page provides educational information about the genetic risks and geographic distribution of ATTRv V30M amyloidosis. It is not a substitute for professional genetic counseling or medical advice.
Get notified when new evidence is published on ATTRV30M amyloidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.